Janux Therapeutics Inc (JANX)
29.12 x 1 32.50 x 1
Post-market by (Cboe BZX)
30.83 -0.91 (-2.87%) 03/25/25 [NASDAQ]
29.12 x 1 32.50 x 1
Post-market 30.83 unch (unch) 16:26 ET
for Tue, Mar 25th, 2025
Try Excel 
Watch
-
Add or delete the symbol from one or more Watchlists.
-
Create New Watchlist
This name already in use.
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 430,605 | 26,754 | 14,662 | 212,803 | 19,205 |
| Marketable Securities | 594,568 | 631,277 | 631,631 | 438,960 | 324,823 |
| Receivables | N/A | N/A | 7,500 | 519 | N/A |
| TOTAL | $1,033,666 | $666,321 | $661,939 | $658,666 | $349,241 |
| Non-Current Assets | |||||
| PPE Net | 4,864 | 5,373 | 5,940 | 6,517 | 7,003 |
| Other Non-Current Assets | 22,986 | 23,325 | 23,533 | 23,801 | 24,163 |
| TOTAL | $27,850 | $28,698 | $29,473 | $30,318 | $31,166 |
| Total Assets | $1,061,516 | $695,019 | $691,412 | $688,984 | $380,407 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,026 | 2,462 | 1,253 | 2,254 | 2,424 |
| Accrued Expenses | 11,684 | 13,022 | 8,568 | 5,810 | 7,387 |
| TOTAL | $17,459 | $17,173 | $11,545 | $10,609 | $13,033 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | 94 | 972 | 1,705 |
| aiOther Non-Current Liabilities | 21,276 | 21,742 | 22,190 | 22,612 | 23,025 |
| TOTAL | $21,276 | $21,742 | $22,190 | $22,612 | $23,025 |
| Total Liabilities | $38,735 | $38,915 | $33,735 | $33,221 | $36,058 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 59,105 | 52,482 | 52,165 | 51,851 | 51,660 |
| Common Shares | 59 | 52 | 52 | 51 | 46 |
| Retained earnings | -237,757 | -217,541 | -189,482 | -183,523 | -168,763 |
| Other shareholders' equity | 2,163 | 7,831 | -1,616 | -524 | 665 |
| TOTAL | $1,022,781 | $656,104 | $657,677 | $655,763 | $344,349 |
| Total Liabilities And Equity | $1,061,516 | $695,019 | $691,412 | $688,984 | $380,407 |